Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a...

Area of Science:

• Oncology
• Pharmacology
• Genomics

Background:

• Advanced EGFR-mutant non-small cell lung cancer (NSCLC) presents challenges in treatment selection.
• Identifying optimal therapies that balance efficacy and safety is crucial for patient outcomes.

Purpose of the Study:

• To conduct a Bayesian network meta-analysis comparing various treatments for advanced EGFR-mutant NSCLC.
• To rank individual treatments and medication classes based on progression-free survival (PFS) and overall survival (OS).
• To evaluate treatment efficacy concerning specific EGFR genomic aberration statuses.

Main Methods:

• A Bayesian network secondary analysis was performed on data from 41 eligible studies.
• Treatments were compared for PFS and OS using hazard ratios (HR) and 95% credible intervals (CrI).
• Analyses included evaluations of objective response rate (ORR), duration of response (DoR), and adverse events.

Main Results:

• For PFS, osimertinib (Osi) and erlotinib (Erlo) + bevacizumab (Bev) were top-ranking individual treatments.
• For OS, Osi, cetuximab (Cet) + Bev + platinum-based therapy (Plat), and cilengitide (Cil) + Cet + Plat showed high rankings.
• Specific EGFR mutations (exon 19 deletion vs. exon 21 L858R) influenced the superiority of certain treatments like Erlo+Bev and Osi.

Conclusions:

• Osimertinib, Erlo+Bev, and Erlo+Bev+Plat are recommended for advanced EGFR-mutant NSCLC, considering both PFS and OS, while monitoring adverse events.
• Immunotherapy (IT) + anti-VEGFR (aVEGFR) + Plat shows potential but requires further clinical validation.
• Treatment choice should be individualized based on specific EGFR mutation status and patient tolerance to adverse events.